Comparative Pharmacology
Head-to-head clinical analysis: AXIRON versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXIRON versus TESULOID.
AXIRON vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
One or two pump actuations (30 mg per actuation) applied to the axilla once daily; dose range 30-90 mg daily.
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone is approximately 10-100 minutes after intravenous injection, but for Axiron (testosterone topical solution), the apparent half-life is about 1-2 hours due to continued absorption from the skin and distribution/elimination. Clinically, steady state is achieved after about 2 weeks of daily application.
16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (about 90%) and about 6% in feces via bile. Approximately 90% of a dose is excreted in urine, with the remainder in feces.
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category C
Category C
Androgen
Androgen